homemarket NewsUS FDA issues 13 observations to Lupin's Novel Laboratories

US FDA issues 13 observations to Lupin's Novel Laboratories

US FDA issues 13 observations to Lupin's Novel Laboratories
Profile image

By PTI Apr 4, 2022 4:44:46 PM IST (Updated)

The USFDA (US Food and Drug Administration) has concluded an inspection at Lupin's wholly-owned subsidiary Novel Laboratories, Inc., based in Somerset, New Jersey. The inspection commenced on March 7, 2022 and concluded on March 30, 2022, Lupin Ltd said in a regulatory filing.

Pharma major Lupin Ltd on Thursday said the USFDA has issued 13 observations to its US-based wholly-owned subsidiary Novel Laboratories, Inc after an inspection.

Recommended Articles

View All

The USFDA (US Food and Drug Administration) has concluded an inspection at the company's wholly-owned subsidiary Novel Laboratories, Inc., based in Somerset, New Jersey. The inspection commenced on March 7, 2022 and concluded on March 30, 2022, Lupin Ltd said in a regulatory filing.
Also Read
"The inspection closed with thirteen observations. We are confident of addressing these observations and will work closely with the Agency to address their concerns. We uphold quality and compliance with utmost importance and are committed to be compliant with Good Manufacturing Practice standards across all our facilities," it said.
The company does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility. The facility contributes less than 5 percent of the company's global revenues.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng